Diatos Moves Its Lead Drug Toward Clinical Trials in Europe

17-Dec-2004

Diatos S.A. announced the positive review and regulatory clearance of its lead drug DTS-201 Investigational Drug application by the Ethics Committee of Toulouse 1 (France). The AFSSAPS (French Health Products Safety Agency) has already been notified and the company will conduct this initial Phase I study beginning early 2005 in three leading oncology clinical centers in France and Belgium. The Phase I trials will mainly study the safety and pharmacokinetics of DTS-201, a doxorubicin prodrug that can be delivered selectively to tumors, in patients with advanced or metastatic solid tumors.

"This regulatory approval of the DTS-201 Investigational Drug application and the imminent initiation of clinical trials for DTS-201 in Europe is a significant milestone for Diatos," said Dr. John Tchelingerian, President and Chief Executive Officer. "Since we in-licensed DTS-201 from Medarex in April 2003 as a research compound, we have demonstrated our ability to rapidly and professionally move the drug into a clinical development stage. I am very pleased with the progress we have made with DTS-201, advancing our core focus in oncology drug development."

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?